Amplify Weight Loss Drug & Treatment ETF (THNR) is currently trading at $24.70. You can also track daily change, historical performance, trading volume and other key ETF details on this page.

Indian investors can buy Amplify Weight Loss Drug & Treatment ETF (THNR) by opening a US investing account through a platform that provides access to US stocks and ETFs, completing the required verification, transferring funds under the Liberalised Remittance Scheme (LRS), and placing an order in USD.

Yes, Indian residents and NRIs can invest in Amplify Weight Loss Drug & Treatment ETF (THNR) through platforms that offer access to US-listed stocks and ETFs, subject to applicable regulations, including RBI’s Liberalised Remittance Scheme (LRS) guidelines.

The expense ratio of Amplify Weight Loss Drug & Treatment ETF (THNR) is 0.58%. It represents the annual operating cost charged by the ETF provider for managing the fund and tracking its underlying index.

Amplify Weight Loss Drug & Treatment ETF (THNR)’s top holdings currently include Eli Lilly and Company, Novo Nordisk A/S, and Amgen Inc. The ETF’s complete holdings list, allocation and sector exposure are available in the Holdings section on this page.

Many platforms offering US ETF investing allow fractional investing, enabling Indian investors to buy a portion of Amplify Weight Loss Drug & Treatment ETF (THNR) instead of a full share. This allows investment based on a fixed dollar amount.

Gains from Amplify Weight Loss Drug & Treatment ETF (THNR) are generally taxed in India based on the applicable holding period and tax rules. Dividends may be subject to US withholding tax and Indian taxation rules. The final tax treatment depends on individual circumstances.

Remittances under the Liberalised Remittance Scheme (LRS) for overseas investments, including US ETFs like Amplify Weight Loss Drug & Treatment ETF (THNR), may attract TCS above specified thresholds. Applicable rates and limits are determined by government regulations and may change over time.

Amplify Weight Loss Drug & Treatment ETF (THNR)’s current assets under management (AUM) are $5.73M. AUM represents the total market value of assets managed by the ETF and indicates the size of the fund.

Amplify Weight Loss Drug & Treatment ETF (THNR)’s price-to-earnings (P/E) ratio is 17.37. It represents the weighted valuation of the companies held within the ETF relative to their earnings.

You can compare Amplify Weight Loss Drug & Treatment ETF (THNR) with Health Care Select Sector SPDR® Fund (XLV), Vanguard Health Care Index Fund ETF Shares (VHT), and iShares Biotechnology ETF (IBB) based on metrics such as expense ratio, AUM, P/E ratio, holdings, liquidity and historical returns in the Peers & Comparison section.

Amplify Weight Loss Drug & Treatment ETF (THNR)’s NAV represents the per-unit value of the ETF’s underlying holdings after adjusting for expenses and liabilities. It is calculated once daily after markets close and may differ from the ETF’s live market price.